Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Equity Average (2019 - 2025)

Historic Equity Average for BioNexus Gene Lab (BGLC) over the last 7 years, with Q3 2025 value amounting to $7.2 million.

  • BioNexus Gene Lab's Equity Average fell 2427.19% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year decrease of 2427.19%. This contributed to the annual value of $9.0 million for FY2024, which is 1015.63% up from last year.
  • Per BioNexus Gene Lab's latest filing, its Equity Average stood at $7.2 million for Q3 2025, which was down 2427.19% from $7.6 million recorded in Q2 2025.
  • Over the past 5 years, BioNexus Gene Lab's Equity Average peaked at $9.7 million during Q4 2023, and registered a low of $6.1 million during Q2 2023.
  • For the 5-year period, BioNexus Gene Lab's Equity Average averaged around $7.6 million, with its median value being $7.2 million (2022).
  • In the last 5 years, BioNexus Gene Lab's Equity Average surged by 8394.2% in 2021 and then tumbled by 2427.19% in 2025.
  • BioNexus Gene Lab's Equity Average (Quarter) stood at $7.1 million in 2021, then decreased by 8.03% to $6.5 million in 2022, then surged by 47.8% to $9.7 million in 2023, then dropped by 8.45% to $8.9 million in 2024, then fell by 19.04% to $7.2 million in 2025.
  • Its Equity Average stands at $7.2 million for Q3 2025, versus $7.6 million for Q2 2025 and $8.0 million for Q1 2025.